X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JS201 is a bifunctional fusion protein developed by Junshi using its proprietary technology that can simultaneously target PD-1 and TGF-β (transforming growth factor-β). First product targeting PD-1/TGF-β approved for a clinical trial application in China.
Lead Product(s): JS201
Therapeutic Area: Oncology Product Name: JS201
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Innovent Biologics has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which targets the COVID-19 virus, an independently-developed project by Innovent.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005).
Lead Product(s): LAE005,Afuresertib
Therapeutic Area: Oncology Product Name: LAE005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
